

# Ingenamine G and Cyclostelletamines G–I, K, and L from the New Brazilian Species of Marine Sponge *Pachychalina* sp.

Jaine H. H. L. de Oliveira,<sup>†</sup> Achim Grube,<sup>‡</sup> Matthias Köck,<sup>‡</sup> Roberto G. S. Berlinck,<sup>\*,†</sup> Mario L. Macedo,<sup>§</sup> Antonio G. Ferreira,<sup>§</sup> and Eduardo Hajdu<sup>⊥</sup>

Instituto de Química de São Carlos, Universidade de São Paulo, CP 780, CEP 13560-970, São Carlos, SP, Brazil, Alfred-Wegener-Institut für Polar- und Meeresforschung in der Helmholtz-Gemeinschaft, Am Handelshafen 12, D-27570 Bremerhaven, Germany, Departamento de Química, Universidade Federal de São Carlos, São Carlos, SP, Brazil, and Museu Nacional, Universidade Federal do Rio de Janeiro, Quinta da Boa Vista, s/n, 20940-040, Rio de Janeiro, RJ, Brazil

Received April 12, 2004

The chemical investigation of the cytotoxic and antituberculosis active MeOH crude extract of the marine sponge *Pachychalina* sp. led to the isolation of six new nitrogenous metabolites, including ingenamine G (**1**), as well as a mixture of new cyclostelletamines G, H, I, K, and L (**10–14**) with the known cyclostelletamines A–F (**4–9**). Structural assignments of compound **1** were based on the analysis of MS and NMR data, while the structures of compounds **10–14** could be established by HPLC-MS/MS analysis. Ingenamine G displayed cytotoxic activity against HCT-8 (colon), B16 (leukemia), and MCF-7 (breast) cancer cell lines, antibacterial activity against *Staphylococcus aureus* (ATCC 25923), *Escherichia coli* (ATCC 25922), and four oxacilin-resistant *S. aureus* strains, and antimycobacterial activity against *Mycobacterium tuberculosis* H37Rv.

Since the isolation of halitoxins by Schmitz's group in 1978 from sponges of the genus *Haliclona* (currently *Amphimedon*),<sup>1</sup> marine sponges in the order Haplosclerida have proven to be an exceptionally rich source of both alkylopyridine and alkyloperidine alkaloids. Comprehensive reviews of this structural class of secondary metabolites have appeared in 1996,<sup>2</sup> 1997,<sup>3</sup> and 2000.<sup>4,5</sup> Not only are these alkaloids considered chemotaxonomic markers of Haplosclerid sponges,<sup>2,3</sup> but many of them present potent biological activities. Such is the case for the antituberculosis and antiviral manadomanzamines from *Acanthostrongylophora* sp.,<sup>6</sup> the cytotoxic and strongly antibiotic arenosclerins from *Arenosclera brasiliensis*,<sup>7,8</sup> the anti-malarial manzamines,<sup>9</sup> and for xestospongins A, C, and D, araguspongine B, and demethylxestospongine B, a group of macrocyclic bis-1-oxaquinolizidines isolated from *Xestospongia* sp., which are potent blockers of IP<sub>3</sub>-mediated Ca<sup>2+</sup> release from endoplasmic reticulum vesicles of rabbit cerebellum.<sup>10</sup>

In our current program for the investigation of biologically active natural products from marine invertebrates,<sup>11</sup> we have recently prioritized the chemical investigation of the crude MeOH extract of a new species of marine sponge, *Pachychalina* sp. (Pinheiro, Berlinck, Hajdu, 2004), which displayed potent cytotoxic activity against HCT-8 colon cancer cells and B16 murine melanoma cancer cells, as well as antituberculosis activity against *Mycobacterium tuberculosis* H37Rv. A preliminary TLC analysis of the *Pachychalina* sp. MeOH extract indicated the presence of a very complex mixture of alkaloids. Herein we report the results of our initial efforts in identifying these alkaloids, which include the isolation of one new ingenamine-related alkaloid and five new cyclostelletamine derivatives.

## Results and Discussion

The crude MeOH extract of *Pachychalina* sp. was subjected to a solvent–solvent partition with EtOAc and

with n-BuOH. After evaporation, the EtOAc extract was dissolved in 9:1 MeOH–H<sub>2</sub>O and partitioned with hexane. The 90% MeOH extract was evaporated, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>–0.5 N HCl. The organic fraction was collected (named CH<sub>2</sub>Cl<sub>2</sub>-acid). The aqueous fraction was basified (1 N NaOH) and partitioned with CH<sub>2</sub>Cl<sub>2</sub>. This organic fraction was designed CH<sub>2</sub>Cl<sub>2</sub>-basic.

Compound **1** was isolated from the CH<sub>2</sub>Cl<sub>2</sub>-basic extract by a series of chromatographic separations as an optically active glassy solid. Its FABMS showed a quasi molecular ion peak at *m/z* 479, on which a high-resolution measurement (measd 479.40007; calcd 479.40014) indicated the formula C<sub>32</sub>H<sub>51</sub>N<sub>2</sub>O with nine degrees of unsaturation. Considering the four double bonds, indicated by analysis of the BBD and DEPT <sup>13</sup>C NMR spectra, the structure of **1** must have five rings. Additionally, analysis of the NMR data indicated the presence of three sp<sup>3</sup> methines (δ 62.1, 40.4, and 37.6), one sp<sup>3</sup> (δ 44.6) and one sp<sup>2</sup> (δ 144.5) quaternary carbons, and five typical nitrogen-substituted methylene resonances (δ 50.6, 51.2, 56.3, 58.0, 59.4), which suggested an ingenamine-type skeleton for **1**. Dereplication within the MARINLIT was strongly indicative that **1** belongs to the ingenamine/ingamine,<sup>12</sup> keramaphidin,<sup>13</sup> and xestocyclamine<sup>14</sup> class of alkaloids. This hypothesis was further supported by comparison of the <sup>13</sup>C NMR data of **1** with those of ingenamine F (**2**)<sup>12c</sup> and keramaphidin B (**3**),<sup>12c,13</sup> in particular chemical shifts of <sup>13</sup>C belonging to the tricyclic central core of these compounds (see Table 2 in the Supporting Information). Extensive analysis of NMR spectra including HSQC, HMBC, <sup>1</sup>H–<sup>1</sup>H COSY, HSQC-TOCSY, and NOESY confirmed this assumption. In the COSY spectrum, we observed a vicinal <sup>1</sup>H–<sup>1</sup>H correlation between H-4 and H-5 (δ 2.40, m), along with several <sup>1</sup>H–<sup>1</sup>H long-range correlations between the two hydrogens of the CH<sub>2</sub>-9 methylene (δ 1.79 and 1.30) and H-12a (δ 3.35) and H-20a (δ 1.82); between the CH<sub>2</sub>-10 methylene signal at δ 3.15 and H-12a; and between both CH<sub>2</sub>-12 hydrogens (δ 3.35 and 2.24) and both CH<sub>2</sub>-21 hydrogens (δ 3.15 and 2.98). More informative were the long-range couplings detected in the HMBC spectra (6, 8, 12, and 15 Hz) and in the HSQC-TOCSY spectrum, which showed <sup>1</sup>H–<sup>13</sup>C cou-

\* To whom correspondence should be addressed. Tel: +55-16-2739954. Fax: +55-16-2739952. E-mail: rgsberlinck@iqsc.usp.br.

<sup>†</sup> Instituto de Química de São Carlos, Universidade de São Paulo.

<sup>‡</sup> Alfred-Wegener-Institut für Polar- und Meeresforschung.

<sup>§</sup> Departamento de Química, Universidade Federal de São Carlos.


<sup>⊥</sup> Museu Nacional, Universidade Federal do Rio de Janeiro.

plings between H-2 ( $\delta$  2.95) and C-4 ( $\delta$  124.4); between H-4 ( $\delta$  6.09) and C-2 ( $\delta$  62.1), C-5 ( $\delta$  37.6), C-33 ( $\delta$  35.1), and C-34 ( $\delta$  37.9); between H-5 ( $\delta$  2.40) and C-7 ( $\delta$  44.6) and C-12 ( $\delta$  51.2); between H-6a ( $\delta$  3.10) and C-4 and C-5; between both CH<sub>2</sub>-6 hydrogens and C-9 ( $\delta$  24.9); between H9a ( $\delta$  1.79) and C-7, C-10 ( $\delta$  50.6); between H9b ( $\delta$  1.30) and C-8 ( $\delta$  40.4) and C-12; between both CH<sub>2</sub>-10 hydrogens and C-8; between CH<sub>2</sub>-12 hydrogens and C-7, C-8, C-9, and C-10; between H-21b and C-12; and finally between H-34 and C-3 ( $\delta$  144.5). These data enabled us to define the “cage-like” central core of **1** as identical to that of **2** and **3**, including the relative stereochemistry, since the “central core” structure substituted by the two N-alkyl bridges supports only one relative stereochemistry. Therefore, structural differences must be present in the two N-alkyl bridges of **1**. Careful analysis of the NMR data indicated that the N-alkyl bridge connecting N-1 to C-7 consisted of eight carbons, in agreement with the structures of ingenamines A–D, ingamines,<sup>12</sup> keramaphidin B,<sup>13</sup> and xestocyclamine A.<sup>14</sup> In the case of these previously reported compounds, this chain contained either one double bond at C-16 or at C-17 or three nonconjugated insaturations at C-15, C-18, and C-21 within the structures of ingenamines E and F.<sup>12c</sup> However, compound **3** showed two conjugated double bonds at C-15 and C-17, with a carbinol group at C-19. Analysis of the NMR data clearly indicated that the methylene CH<sub>2</sub>-13 ( $\delta$  58.0) was vicinally coupled to the methylene CH<sub>2</sub>-14 ( $\delta$  26.5), which was in turn at the allylic position to CH-15 ( $\delta$  132.6). The conjugated system was clearly observed through <sup>1</sup>H–<sup>1</sup>H COSY and long-range HMBC and HSQC-TOCSY couplings from CH-15 to CH-18 ( $\delta$  134.5) through CH-16 ( $\delta$  126.7) and CH-17 ( $\delta$  125.6). The *Z,Z* stereochemistry was assigned to the C-15, C-17 unsaturated system on the basis of the coupling constants measured between H-15 and H-16 ( $J$  = 9.5 Hz) and between H-17 and H-18 ( $J$  = 9.0 Hz), as well as on the C-14 ( $\delta$  26.5) and C-19 ( $\delta$  67.3) high-field chemical shifts. The carbinol hydrogen methine CHO-19 ( $\delta$  4.78) showed <sup>1</sup>H–<sup>1</sup>H couplings with both CH-18 ( $\delta$  5.37) and CH<sub>2</sub>-20 ( $\delta$  1.82 and 1.46), as well as <sup>1</sup>H–<sup>13</sup>C long-range correlations with carbons C-16 and C-17. Finally, the methylene CH<sub>2</sub>-20 showed key <sup>1</sup>H–<sup>1</sup>H and <sup>1</sup>H–<sup>13</sup>C correlations with CH<sub>2</sub>-19, C-7, and CH<sub>2</sub>-9. The remaining N-alkyl bridge consisted of 14 carbons, two of which participate in a double bond. The position of the unsaturation was unambiguously established by analysis of the <sup>1</sup>H–<sup>1</sup>H COSY spectrum, which showed a long-range <sup>1</sup>H–<sup>1</sup>H coupling between CH<sub>2</sub>-12 and CH<sub>2</sub>-21, as well as vicinal <sup>1</sup>H–<sup>1</sup>H couplings between CH<sub>2</sub>-21 and CH<sub>2</sub>-22, between CH<sub>2</sub>-22 and CH-23, and finally between CH-23 and CH-24. The position of this double bond was also confirmed by analysis of the HMBC and HSQC-TOCSY spectra, which displayed long-range couplings between C-12 and the hydrogens of CH<sub>2</sub>-21, between C-21 and the hydrogens of CH<sub>2</sub>-22, CH-23, and CH-24, between C-22 and CH<sub>2</sub>-21, CH-23, and CH-24, between C-23 and CH<sub>2</sub>-22 and CH<sub>2</sub>-25, and finally between C-24 and CH<sub>2</sub>-22 and CH<sub>2</sub>-25. The *Z* stereochemistry was assigned to this double bond on the basis of the H-23/H-24 coupling constant ( $J$  = 10.3 Hz) and the <sup>13</sup>C shielded chemical shifts of both CH<sub>2</sub>-22 ( $\delta$  22.5) and CH<sub>2</sub>-25 ( $\delta$  27.5). The <sup>1</sup>H and <sup>13</sup>C assignments of the remaining methylene chain were largely based on a detailed scrutiny of <sup>1</sup>H–<sup>13</sup>C long-range couplings observed in HMBC and HSQC-TOCSY spectra. Both carbons C-33 and C-34 were shown to be long-range coupled to H-4, establishing the attachment point of the second N-alkyl chain to the C-3/


C-4 double bond. We proposed the name ingenamine G for compound **1**.

Although the absolute stereochemistry of ingenamine G (**1**) herein isolated from *Pachychalina* sp. was not established, the similarity of both the specific rotation and NMR data observed for the <sup>1</sup>H and <sup>13</sup>C at the central tricyclic core strongly suggests that it has the same absolute stereochemistry as ingenamine F (**2**). We have not attempted to establish the absolute stereochemistry of **1**, due to previous negative results on derivatizing with MTPA a similar conjugated allylic alcohol function in the arenosclerins.<sup>7</sup> Ingenamine G (**1**) displayed cytotoxic activity against HCT-8 (colon), B16 (leukemia), and MCF-7 (breast) cancer cell lines at the level of 8.6, 9.8, and 11.3  $\mu$ g/mL, respectively, and antibacterial activity against *Staphylococcus aureus* (ATCC 25923) at 105  $\mu$ g/mL, *Escherichia coli* (ATCC 25922) at 75  $\mu$ g/mL, and four oxacilin-resistant *S. aureus* strains, two of which at concentrations between 10 and 50  $\mu$ g/mL, as well as antimycobacterial activity against *Mycobacterium tuberculosis* H37Rv at 8  $\mu$ g/mL.

Chromatographic separation of the n-BuOH crude extract (see Experimental Section) led to the isolation of two fractions containing 3-alkylpyridinium alkaloids. <sup>1</sup>H NMR analysis of these fractions showed the very characteristic pattern observed for these compounds, which includes four aromatic hydrogen signals at  $\delta$  9.17 (s, H-2), 9.05 (d, 7.1 Hz, H-6), 8.45 (d,  $J$  = 7.1 Hz, H-4), and 8.09 (t,  $J$  = 7.1 Hz, H-5) as well as aliphatic hydrogen signals at  $\delta$  4.63 (t,  $J$  = 6.7 Hz, CH<sub>2</sub>-7), 1.89 (m, CH<sub>2</sub>-8), 2.80 (t, 6.7 Hz, CH<sub>2</sub>-9), and 1.63 (m, CH<sub>2</sub>-10) and a broad singlet between  $\delta$  1.14 and 1.21 (methylene chain).<sup>15,16</sup> Typical <sup>13</sup>C resonances of 3-alkylpyridine compounds were also observed in the HSQC spectrum. Although a preparative HPLC purification of these fractions lead to a single HPLC peak, further HPLC-MS/MS (ESI-TOF, API-CID) analyses of these fractions revealed the presence of an alkaloid mixture of the known cyclostellamines A–F (**4–9**), together with the new cyclostellamines G (**10**), H (**11**), I (**12**), K (**13**), and L (**14**). The known cyclostellamines A–F (**4–9**) consist



<b>4</b> x = 3, y = 3	<b>10</b> x = 2, y = 3
<b>5</b> x = 3, y = 4	<b>11</b> x = 1, y = 3
<b>6</b> x = 4, y = 4	<b>12</b> x = 1, y = 4
<b>7</b> x = 3, y = 5	<b>13</b> x = 1, y = 5
<b>8</b> x = 4, y = 5	<b>14</b> x = 2, y = 5
<b>9</b> x = 5, y = 5	



**Figure 1.** ESI-API-CID-mass spectrum of cyclostellettamine H (**11**, top) and isocyclostellettamine B (**5**, bottom). The peak at  $m/z$  239 is the doubly charged intact molecule ion  $M^{2+}$ , which is proven by the mass difference of isotope peaks of one-half mass units. The other singly charged peaks at  $m/z$  232 and  $m/z$  246 are the main fragments of cyclostellettamine H (**11**).

of alkyl chains with 12–14 carbon atoms each ( $C_x$  or  $C_y$ ); the sum of both alkyl chains is therefore 24–28 ( $\Sigma[C_x + C_y]$ ). The HPLC-MS/MS analysis showed five new cyclostellettamines with  $\Sigma[C_x + C_y] = 22, 23$  (two different ones), 24, and 25. Dimeric pyridinium compounds undergo a mass spectral cleavage that leads to a ring opening (Hofmann fragmentation). Therefore, usually the singly charged molecular ion  $[M - H]^+$  is observed at one mass unit less than its actual molecular weight. In our investigations only the doubly charged molecular ion  $M^{2+}$  was detected. This information together with the NMR chemical shifts proves unambiguously the cyclostellettamine core. The distribution of the carbon atoms between the two alkyl chains ( $C_x + C_y$ ) required information about the MS fragments (HR-MS/MS analysis). Under API-CID conditions the two singly charged main fragments (probably due to two Hofmann fragmentations that split the molecules into halves) could be observed and used for the differentiation of the previously known cyclostellettamines (see Figure 1). The main fragments were identified on the basis of their intensity in the MS/MS spectrum (under API-CID conditions). Therefore, the new cyclostellettamines with  $\Sigma[C_x + C_y] = 22$  and 23 were identified as cyclostellettamines G (**10**, **11** + **12**),<sup>17</sup> H (**11**, **10** + **12**), and I (**12**, **10** + **13**). The sum  $\Sigma[C_x + C_y] = 24$  and 25 was already known for cyclostellettamines A (**4**) and B (**5**). However, the information from the two main fragments indicated the occurrence of two further new derivatives, cyclostellettamines K (**13**, **10** + **14**) and L (**14**, **11** + **14**). We suggest that the name cyclostellettamine J should be given to the **11** + **13** analogue, which has not been isolated yet.

Up to the present, the marine sponge *Pachychalina* sp. contain an interesting secondary metabolism profile. Although alkyipyridinium and alkyipiperidine alkaloids are commonly found within sponges of the order Haplosclerida, they are rarely found simultaneously. To the best of our knowledge, only the Mediterranean marine sponge *Reniera sarai* possesses halitoxins<sup>18</sup> and alkyipiperidine alkaloids (sarains and isosarains).<sup>19</sup> However, since bis-alkyipyridine alkaloids are currently considered to be the biogenetic precursors of their respective alkyipiperidine counterparts, as originally suggested by Cimino<sup>19b</sup> as well as by Baldwin and Whitehead,<sup>20</sup> it is not surprising to have isolated both alkaloid classes within a single species of marine sponge. It is possible that the co-occurrence of both alkyipyridines and alkyipiperidines within sponges of the order Haplosclerida is more common than it has been reported. However, since alkyipyridine alkaloids are considered as nuisance compounds that interfere in various bioassays,<sup>11,21</sup> they are not usually investigated. We are currently identifying minor alkaloids of the marine sponge *Pachychalina* sp.

## Experimental Section

**General Experimental Procedures.** Optical rotations were measured on a Perkin-Elmer 241 MC polarimeter at 29 °C. IR spectra (film on Si plate) were recorded on a FT-IR Bomem MB102 infrared spectrometer. The NMR spectra were recorded either on a Bruker ARX400 9.4 T instrument, operating at 400.35 MHz for  $^1H$  and 100.10 MHz for  $^{13}C$  channels, respectively, or on a Bruker DRX500 11.7 T, operating at 500.13 MHz for  $^1H$  and 125.76 MHz for  $^{13}C$ , respectively. All NMR spectra were obtained at 25 °C using TMS as internal



**Table 1.** <sup>1</sup>H, <sup>13</sup>C, COSY, HSQC-TOCSY, and HMBC NMR Data Recorded in MeOH-*d*<sub>4</sub> for Ingenamine G (1)

position	$\delta$ <sup>13</sup> C <sup>a</sup>	$\delta$ <sup>1</sup> H (mult, <i>J</i> in Hz)	COSY <sup>c</sup>	HSQC-TOCSY <sup>a,c</sup>	HMBC <sup>b,c</sup>
CH-2	62.1	2.95		H17	H4
C-3	144.5				H33ab, H34
CH-4	124.4	6.09 (m)	H5	H2, H5	H6b
CH-5	37.6	2.40 (m)	H4	H6b	H4
CH <sub>2</sub> -6	56.3	3.10 (m); 1.96 (m)			
C-7	44.6				H5, H9a, H12ab, H20
CH-8	40.4	1.28 (m)		H9b, H10	H10, H12
CH <sub>2</sub> -9	24.9	1.79 (m); 1.30 (m)	H12a, H20	H6, H12a	H12, H20b
CH <sub>2</sub> -10	50.6	3.15 (m)	H12a	H9a, H12a	H12a
CH <sub>2</sub> -12	51.2	3.35 (m); 2.24 (m)	H21ab		H5, H9b, H21b
CH <sub>2</sub> -13	58.0	2.72 (m); 2.33 (m)		H14a, H15	
CH <sub>2</sub> -14	26.5	2.47 (m); 2.07 (m)	H15	H13a	H16
CH-15	132.6	5.64 (m, 9.5, 5.4)	H16		H17
CH-16	126.7	6.37 (q, 10.6)	H15	H15, H17, H19	H17, H18
CH-17	125.6	6.33 (q, 10.6)		H18	H15, H19
CH-18	134.5	5.37 (m, 9.0, 5.6)	H17	H20b	H15, H16, H20a
CH-19	67.3	4.78 (ddd, 3.9, 5.5, 9.7)	H18, H20a	H17	H16, H17
CH <sub>2</sub> -20	36.4	1.82 (m); 1.46 (m)	H9, H19	H20a	H19
CH <sub>2</sub> -21	59.4	3.15 (m, 4.3, 8.1); 2.98 (m, 4.3, 8.3)	H12ab	H22ab, H23, H24	H22ab, H23
CH <sub>2</sub> -22	22.5	2.65 (m); 2.27 (m)	H21ab, H23, H24	H21ab, H22ab, H23	H21ab, H23, H24
CH-23	124.4	5.33(m)	H24		H22ab, H25ab
CH-24	134.5	5.72 (dd, 8.2, 10.3)	H25a		H22ab, H25ab
CH <sub>2</sub> -25	27.5	2.24 (m); 1.96 (m)	H24	H23, H24	H21b, H23, H24, H26
CH <sub>2</sub> -26	28.9	1.40 (m)	H25b		H25b, H9
CH <sub>2</sub> -27	28.2 <sup>d</sup>	1.24 (m)			
CH <sub>2</sub> -28	27.9 <sup>d</sup>	1.24 (m)		H29	
CH <sub>2</sub> -29	26.2	1.02 (m)	H30	H26	H33b
CH <sub>2</sub> -30	27.7 <sup>d</sup>	1.28 (m)		H29	H30, H33ab
CH <sub>2</sub> -31	27.5	1.44(m)	H33a	H30, H32, H33a	H32, H33b, H34b
CH <sub>2</sub> -32	25.2	1.59 (m)	H33ab	H30, H31, H33a	H31, H33ab
CH <sub>2</sub> -33	35.1	2.15 (m); 2.05 (m)		H31, H32	H4, H32
CH <sub>2</sub> -34	37.9	2.05 (m); 1.36 (m)		H4, H29, H30	H30

<sup>a</sup> Assignments by inverse detection at 400 MHz (HSQC). <sup>b</sup> Inverse detection at 400 MHz, for  $^nJ_{^{13}\text{C}-^1\text{H}} = 8.3$ . <sup>c</sup> a and b denote downfield and upfield resonances respectively of a geminal pair. <sup>d</sup> Assignments may be reversed.

reference. Low-resolution mass spectra were recorded on a VG-7070 mass spectrometer operating at a nominal accelerating voltage of 70 eV. High-resolution mass spectra were recorded at a nominal resolution of 5000 or 10000 as appropriate. All spectra were obtained using EI, FAB, or CI ionization techniques using perfluorokerosene, 3-nitrobenzyl alcohol, or poly(ethylene glycol) as the internal standard. LOBAR Lichroprep (Merck) separations were performed with size B (310 × 25 mm) columns. Solvents used for extraction and flash chromatography were glass distilled prior to use. HPLC-grade solvents were utilized without further purification in LOBAR and HPLC separations. TLC analyses were performed with plastic-backed Si gel TLC sheets, eluting with different mixtures of MeOH in CH<sub>2</sub>Cl<sub>2</sub>. Plates were visualized by spraying with Dragendorff reagent. HPLC separations were performed either with a Waters quaternary pump 600, double beam UV detector 2487, and data module 746 or with a Waters autosampler 717, Waters 600 pump, and Waters 2996 photodiode array detector monitored by Waters Millennium 32. For HPLC-MS/MS (API-CID) analysis, fractions were dissolved in 2-propanol. The samples were injected into a HPLC System 1100 Series (Agilent) equipped with a photodiode array detector (Agilent) and a microTOF LC mass spectrometer (Bruker Daltonik). The detection with the DAD was performed at a wavelength of 260 nm. Mass spectra were acquired with an ESI source (Bruker Daltonik). The following ESI inlet conditions were applied: dry gas temperature 180 °C; dry gas flow 10 L/min; nebulizer pressure 1.5 bar; capillary voltage 4500 V. For fragmentation the voltage of the Capillary Exit was set to 150% of the normal voltage and the voltage of Skimmer 1 was set to 133% of the normal voltage.

**Animal Material.** The sponge *Pachychalina* sp. was collected in Ilha do Pai (Father's Island), Niterói, Rio de Janeiro (22°59.205' S–43°05.252' W), on May 9, 2000, at 10–15 m depth, and immediately immersed in EtOH. The whole material was shipped to the Instituto de Química de São Carlos,

Universidade de São Paulo. Voucher specimens are deposited at the Museu Nacional (MNRJ 3098 and 3099).

**Extraction and Isolation.** The sponge (2.0 kg) was separated from the EtOH extract, blended in MeOH, and left overnight. After filtration of the MeOH extract, the solid material was re-extracted with MeOH. Both EtOH and MeOH extracts were pooled and evaporated until 500 mL of an aqueous suspension was obtained. The H<sub>2</sub>O phase was partitioned with EtOAc. Then 25% NH<sub>4</sub>OH was added to the H<sub>2</sub>O phase until pH ~10, and the alkaline phase was partitioned with n-BuOH to yield 5.1 g of a brown gum after evaporation.

The EtOAc extract was evaporated, dissolved in 9:1 MeOH–H<sub>2</sub>O, and partitioned with hexanes (5.9 g of a light brown gum). The aqueous MeOH extract was subsequently evaporated, and the gummy material was solubilized in CH<sub>2</sub>Cl<sub>2</sub>–0.5 N HCl. The CH<sub>2</sub>Cl<sub>2</sub> fraction was collected and named CH<sub>2</sub>Cl<sub>2</sub>-acid (5.03 g of a light greenish gum). NaOH (1 N) was added to the aqueous fraction, which was partitioned with CH<sub>2</sub>Cl<sub>2</sub>. The fraction was named CH<sub>2</sub>Cl<sub>2</sub>-basic (0.87 g of a yellow gum). All extracts were analyzed by TLC and revealed the presence of alkaloids (Dragendorff).

The CH<sub>2</sub>Cl<sub>2</sub>-basic extract was fractionated by chromatography on a cyanopropyl-bonded Sep Pak column (10 g) with a gradient of MeOH in CH<sub>2</sub>Cl<sub>2</sub> to give two fractions. The first fraction was separated by chromatography on a silica gel Sep Pak column (10 g) with a gradient of MeOH in CH<sub>2</sub>Cl<sub>2</sub>, to give four fractions. The second fraction was separated by chromatography on a silica gel Sep Pak column (10 g) with a gradient of 1:1 acetonitrile–MeOH in CH<sub>2</sub>Cl<sub>2</sub>, yielding seven fractions. The fourth one was shown to be pure by <sup>1</sup>H and <sup>13</sup>C NMR, giving 55.7 mg of compound **1** (0.0028% wet weight).

The n-BuOH extract was fractionated by chromatography on an amino-bonded Sep Pak column (10 g) with a gradient of MeOH in CH<sub>2</sub>Cl<sub>2</sub>. Five fractions were obtained. The second and the fourth fractions were subjected to identical separations by chromatography on Sephadex LH20 (1:1 CH<sub>2</sub>Cl<sub>2</sub>–MeOH). The second and third fractions of each of these last separations were shown to be identical by TLC. Therefore, these four

fractions were all pooled and further separated by chromatography on a cyanopropyl-bonded LOBAR column, with a gradient of MeOH in CH<sub>2</sub>Cl<sub>2</sub>. The first, fourth, and fifth fractions obtained from this last separation were purified by HPLC (column: C<sub>18</sub> μBondapak, 7.8 × 300 mm, 10 μm 125 Å; eluents: 9:1 acetonitrile–H<sub>2</sub>O or 7:3 MeOH–H<sub>2</sub>O). The two fractions obtained, AmNL1FN5a (3.0 mg) and AmNL4a (3.0 mg), were further analyzed by HPLC-MS/MS. For the HPLC-MS separation, a XTerra RP-18 column (3.0 × 150 mm, 3.5 μm, Waters) was used. Separation was achieved by applying a 30 min gradient from 20% acetonitrile/80% formic acid (0.1% in water) to 80% acetonitrile/20% formic acid (0.1% in water), then isocratic conditions during 15 min. Total analysis time was 45 min with a flow rate of 0.4 mL/min and an oven temperature of 30 °C.

**Ingenamine G (1):** glassy solid; [α]<sub>D</sub><sup>20</sup> –59.2 (c 0.050, MeOH); UV (MeOH) λ<sub>max</sub> 230 (ε 2500) 283 (ε 625) nm; IR (film on a Si plate) ν<sub>max</sub> 3390 (OH), 2929 (CH), 2858 (CH), 2554 (Bohlmann), 1660, 1447, 1023 cm<sup>-1</sup>; <sup>1</sup>H NMR (MeOH-*d*<sub>4</sub>, 400 MHz), see Table 1; <sup>13</sup>C NMR (MeOH-*d*<sub>4</sub>, 100 MHz), see Table 1; positive HRFABMS *m/z* 479.40007 [M + H]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>52</sub>N<sub>2</sub>O 479.40014).

**Cyclostellettamine G (10):** UV (HPLC-DAD) λ<sub>max</sub> 267 nm; positive ESI-MS *m/z* 239.2126 M<sup>2+</sup> (calcd for C<sub>33</sub>H<sub>54</sub>N<sub>2</sub> 239.2138), Δ*m* = 5.1 ppm. Results for the fragmentation: (a) *m/z* 232.2052 [M – C<sub>17</sub>H<sub>28</sub>N]<sup>+</sup> (calcd for C<sub>16</sub>H<sub>26</sub>N 232.2060), Δ*m* = 3.2; (b) *m/z* 246.2202 [M – C<sub>16</sub>H<sub>26</sub>N]<sup>+</sup> (calcd for C<sub>17</sub>H<sub>28</sub>N 246.2216) Δ*m* = 5.9.

**Cyclostellettamine H (11):** UV (HPLC-DAD) λ<sub>max</sub> 267 nm; positive ESI-MS *m/z* 232.2051 M<sup>2+</sup> (calcd for C<sub>32</sub>H<sub>52</sub>N<sub>2</sub> 232.2060), Δ*m* = 3.6 ppm. Results for the fragmentation: (a) *m/z* 218.1905 [M – C<sub>17</sub>H<sub>28</sub>N]<sup>+</sup> (calcd for C<sub>15</sub>H<sub>24</sub>N 218.1903), Δ*m* = 0.7; (b) *m/z* 246.2216 [M – C<sub>15</sub>H<sub>24</sub>N]<sup>+</sup> (calcd for C<sub>17</sub>H<sub>28</sub>N 246.2216), Δ*m* = 6.7.

**Cyclostellettamine I (12):** UV (HPLC-DAD) λ<sub>max</sub> 267 nm; positive ESI-MS *m/z* 239.2127 M<sup>2+</sup> (calcd for C<sub>33</sub>H<sub>54</sub>N<sub>2</sub> 239.2138), Δ*m* = 4.5 ppm. Results for the fragmentation: (a) *m/z* 218.1909 [M – C<sub>18</sub>H<sub>30</sub>N]<sup>+</sup> (calcd for C<sub>15</sub>H<sub>24</sub>N 218.1903), Δ*m* = 2.7; (b) *m/z* 260.2349 [M – C<sub>15</sub>H<sub>24</sub>N]<sup>+</sup> (calcd for C<sub>18</sub>H<sub>30</sub>N 260.2373) Δ*m* = 9.0.

**Cyclostellettamine K (13):** UV (HPLC-DAD) λ<sub>max</sub> 267 nm; positive ESI-MS *m/z* 246.2198 M<sup>2+</sup> (calcd for C<sub>34</sub>H<sub>56</sub>N<sub>2</sub> 246.2216), Δ*m* = 7.2 ppm. Results for the fragmentation: (a) *m/z* 218.1907 [M – C<sub>19</sub>H<sub>32</sub>N]<sup>+</sup> (calcd for C<sub>15</sub>H<sub>24</sub>N 218.1903), Δ*m* = 1.5; (b) *m/z* 274.2499 [M – C<sub>15</sub>H<sub>24</sub>N]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>32</sub>N 274.2529) Δ*m* = 11.2.

**Cyclostellettamine L (14):** UV (HPLC-DAD) λ<sub>max</sub> 267 nm; positive ESI-MS *m/z* 253.2271 M<sup>2+</sup> (calcd. for C<sub>35</sub>H<sub>58</sub>N<sub>2</sub> 253.2295), Δ*m* = 9.3 ppm. Results for the fragmentation: (a) *m/z* 232.2057 [M – C<sub>19</sub>H<sub>32</sub>N]<sup>+</sup> (calcd for C<sub>16</sub>H<sub>26</sub>N 232.2060), Δ*m* = 1.0; (b) *m/z* 274.2507 [M – C<sub>16</sub>H<sub>26</sub>N]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>32</sub>N 274.2529) Δ*m* = 8.0.

**Acknowledgment.** The authors are indebted to Prof. B. Copp (Department of Chemistry, University of Auckland, Auckland, New Zealand) for his assistance in measuring MS data of compound **1**, as well as to Prof. C. Pessoa and M. O. Moraes (Universidade Federal do Ceará) for the cytotoxicity assays, A. O. de Souza (Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo) for the antituberculosis bioassay, and Prof. G. F. Nascimento (Universidade Metodista de Piracicaba) for the antimicrobial bioassays. The logistic and technical support of the Centro de Biologia Marinha of the Universidade de São Paulo is also greatly appreciated. Financial support was provided to R.G.S.B. by

grants from FAPESP (01/03095-5) and from NIH (CA 67786). J.H.H.L.O. also thank FAPESP for a scholarship. The authors also thank two anonymous reviewers for many suggestions to improve the manuscript.

**Supporting Information Available:** This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References and Notes

- (1) Schmitz, F. J.; Hollenbeak, K. H.; Campbell, D. C. *J. Org. Chem.* **1978**, *43*, 3916–3922.
- (2) Andersen, R. J.; Van Soest, R. W. M.; Kong, F. In *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Pergamon Press: New York, 1996; Vol. 10, pp 301–355.
- (3) Almeida, A. M. P.; Berlinck, R. G. S.; Hajdu, E. *Quím. Nova* **1997**, *20*, 170–185.
- (4) Sepcic, K. *J. Toxicol. Toxin Rev.* **2000**, *19*, 139–160.
- (5) Rodriguez, J. *Stud. Nat. Prod. Chem.* **2000**, *24*, 573–581.
- (6) Peng, J. N.; Hu, J. F.; Kazi, A. B.; Li, Z.; Avery, M.; Peraud, O.; Hill, R. T.; Franzblau, S. G.; Zhang, F. Q.; Schinazi, R. F.; Wirtz, S. S.; Tharnish, P.; Kelly, M.; Wahyuno, S.; Hamann, M. T. *J. Am. Chem. Soc.* **2003**, *125*, 13382–13386.
- (7) Torres, Y. R.; Berlinck, R. G. S.; Magalhães, A.; Schefer, A. B.; Ferreira, A. G.; Hajdu, E.; Muricy, G. *J. Nat. Prod.* **2000**, *63*, 1098–1105.
- (8) Torres, Y. R.; Berlinck, R. G. S.; Nascimento, G. G. F.; Fortier, S. C.; Pessoa, C.; Moraes, M. O. *Toxicol.* **2002**, *40*, 885–891.
- (9) (a) Ang, K. K. H.; Holmes, M. J.; Kara, U. A. K. *Parasitol. Res.* **2001**, *87*, 715–721. (b) Ang, K. K. H.; Holmes, M. J.; Higa, T.; Hamann, M. T.; Kara, U. A. K. *Antimicrob. Agents Chemother.* **2000**, *44*, 1645–1649.
- (10) Gafni, J.; Munsch, J. A.; Lam, T. H.; Catlin, M. C.; Costa, L. G.; Molinski, T. F.; Pessah, I. N. *Neuron* **1997**, *19*, 723–733.
- (11) Berlinck, R. G. S.; Hajdu, E.; Rocha, R. M.; Oliveira, J. H. H. L.; Hernández, I. L. C.; Selegim, M. H. R.; Granato, A. C.; Almeida, E. V. R.; Nuñez, C. V.; Muricy, G.; Peixinho, S.; Pessoa, C. O.; Moraes, M. O.; Cavalcanti, B. C.; Nascimento, G. G. F.; Thiemann, O.; Silva, M.; Souza, A. O.; Minarini, P. R. R. *J. Nat. Prod.* **2004**, *67*, 510–522.
- (12) (a) Kong, F.; Andersen, R. J.; Allen, T. M. *Tetrahedron Lett.* **1994**, *35*, 1643–1646. (b) Kong, F.; Andersen, R. J.; Allen, T. M. *Tetrahedron* **1994**, *50*, 6137–6144. <sup>1</sup>H and <sup>13</sup>C chemical shifts of keramaphidin C have been reassigned. See: (c) Kong, F.; Andersen, R. J. *Tetrahedron* **1995**, *51*, 2895–2906.
- (13) Kobayashi, J.; Tsuda, M.; Kawasaki, N.; Matsumoto, K.; Adachi, T. *Tetrahedron Lett.* **1994**, *35*, 4383–4386.
- (14) Rodriguez, J.; Peters, B. M.; Kurz, L.; Schatzman, R. C.; McCarley, D.; Lou, L.; Crews, P. *J. Am. Chem. Soc.* **1993**, *115*, 10436–10437.
- (15) Volk, C. A.; Köck, M. *Org. Lett.* **2003**, *5*, 2567–2569.
- (16) Fusetani, N.; Asai, N.; Matsunaga, S.; Honda, K.; Yasumuro, K. *Tetrahedron Lett.* **1994**, *35*, 3967–3970.
- (17) We have initially named **11** as cyclostellettamine G and **10** as cyclostellettamine H, since **11** has a smaller number of methylene groups than **10**. However, during the preparation of the manuscript we became aware of the recent isolation of cyclostellettamine G (**10**) by Prof. Fusetani's group, and therefore we have switched the names of both **10** and **11**. Oku, N.; Nagai, K.; Shindoh, N.; Terada, Y.; van Soest, R. W. M.; Matsunaga, S.; Fusetani, N. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 2617–2620.
- (18) Sepcic, K.; Guella, G.; Mancini, I.; Pietra, F.; Della Serra, M.; Menestrina, G.; Macek, P.; Tubbs, K.; Turk, T. *J. Nat. Prod.* **1997**, *60*, 991–996.
- (19) (a) Cimino, G.; de Rosa, S.; de Stefano, S.; Sodano, G. *Pure Appl. Chem.* **1986**, *58*, 375–386. (b) Cimino, G.; de Stefano, S.; Scognamiglio, G.; Sodano, G. *Bull. Soc. Chim. Belg.* **1986**, *95*, 783–800. (c) Cimino, G.; Spinella, S.; Trivellone, E. *Tetrahedron Lett.* **1989**, *30*, 133–136. (d) Cimino, G.; Puliti, R.; Scognamiglio, G.; Spinella, A.; Trivellone, E. *Pure Appl. Chem.* **1989**, *61*, 535–538. (e) Cimino, G.; Mattia, C. A.; Mazzearella, L.; Puliti, R.; Scognamiglio, G.; Trivellone, E. *Tetrahedron* **1989**, *45*, 3863–3872. (f) Cimino, G.; Scognamiglio, G.; Spinella, A. *J. Nat. Prod.* **1990**, *53*, 1519–1525. (g) Cimino, G.; Fontana, A.; Madaio, A.; Scognamiglio, G.; Trivellone, E. *Magn. Reson. Chem.* **1991**, *29*, 327–332. (h) Guo, Y. W.; Madaio, A.; Trivellone, E.; Scognamiglio, G.; Cimino, G. *Tetrahedron* **1996**, *52*, 8341–8348. (i) Guo, Y. W.; Trivellone, E.; Scognamiglio, G.; Cimino, G. *Tetrahedron Lett.* **1998**, *39*, 463–466.
- (20) Baldwin, J. E.; Whitehead, R. C. *Tetrahedron Lett.* **1992**, *33*, 2059–2062.
- (21) Patil, A. D.; Freyer, A. J.; Taylor, P. B.; Carté, B.; Zuber, G.; Johnson, R. K.; Faulkner, D. J. *J. Org. Chem.* **1997**, *62*, 1814–1819.

NP0498713